Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients with Heart Failure with Preserved Ejection Fraction: A Holistic Proteomic Approach

Circulation: Cardiovascular Genetics

Volumn 10, Issue 1, 2017, Pages

  Hage, Camilla ^a,b   Michaëlsson, Erik ^c   Linde, Cecilia ^a,b   Donal, Erwan ^d   Daubert, Jean Claude ^d   Gan, Li Ming ^c,e   Lund, Lars H ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

apoptosis; biomarkers; inflammation; prognosis; proteomics

Indexed keywords

ADRENOMEDULLIN; AGOUTI RELATED PROTEIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CD40 ANTIGEN; CHITINASE 3 LIKE PROTEIN 1; FATTY ACID BINDING PROTEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE ELASTASE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MATRILYSIN; PROLACTIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN A; AUTACOID;

AGED; ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; BLOOD; CLINICAL TRIAL; FRANCE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; LEAST SQUARE ANALYSIS; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN DATABASE; PROTEOMICS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SWEDEN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; DATABASES, PROTEIN; ECHOCARDIOGRAPHY; FEMALE; FRANCE; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; LEAST-SQUARES ANALYSIS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEOMICS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SWEDEN; VENTRICULAR FUNCTION, LEFT;

EID: 85013469399     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.116.001633     Document Type: Article

References (54)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. doi: 10.1056/NEJMoa052256
2. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-2159. doi: 10.1056/NEJMra0800239
3. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the charm-preserved trial. Lancet. 2003;362:777-781. doi: 10.1016/S0140-6736(03)14285-7
4. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-1392. doi: 10.1056/NEJMoa1313731
5. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345. doi: 10.1093/eurheartj/ehl250
6. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467. doi: 2410.1056/NEJMoa0805450. doi: 10.1056/NEJMoa0805450
7. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998-1005. doi: 10.1016/j.jacc.2011.11.040
8. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271. doi: 10.1016/j.jacc.2013.02.092
9. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121-3128. doi: 10.1161/01.CIR.0000147181.65298.4D
10. Januzzi JL Jr. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res. 2013;6:493-500. doi: 10.1007/s12265-013-9459-y
11. Lok SI, Winkens B, Goldschmeding R, van Geffen AJ, Nous FM, van Kuik J, et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail. 2012;14:1249-1256. doi: 10.1093/eurjhf/hfs120
12. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011;4:44-52. doi: 10.1161/CIRCHEARTFAILURE.109.931451
13. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60-68. doi: 10.3109/07853890.2010.538080
14. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61:1498-1506. doi: 10.1016/j.jacc.2012.12.044
15. Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, et al; PARAMOUNT Investigators. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3442-3451. doi: 10.1093/eurheartj/ehu254
16. Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure Eur J Heart Fail. 2011;13:1087-1095. doi: 10.1093/eurjhf/hfr079
17. Glezeva N, Voon V, Watson C, Horgan S, McDonald K, Ledwidge M, et al. Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis. J Card Fail. 2015;21:167-177. doi: 10.1016/j.cardfail.2014.11.004
18. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemometrics. 2002;16:119-128
19. Donal E, Lund LH, Linde C, Edner M, Lafitte S, Persson H, et al. Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. Eur J Heart Fail. 2009;11:198-204. doi: 10.1093/eurjhf/hfn025
20. Assarsson E, Lundberg M, Holmquist G, Björkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9:e95192. doi: 10.1371/journal.pone.0095192
21. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. doi: 10.1093/eurheartj/ehw128
22. Maréchaux S, Rusinaru D, Jobic Y, Ederhy S, Donal E, Réant P, et al. Food and Drug Administration criteria for the diagnosis of drug-induced valvular heart disease in patients previously exposed to benfluorex: A prospective multicentre study. Eur Heart J Cardiovasc Imaging. 2015;16:158-165. doi: 10.1093/ehjci/jeu212
23. Matsue Y, Suzuki M, Nagahori W, Ohno M, Matsumura A, Hashimoto Y, et al. Endothelial dysfunction measured by peripheral arterial tonometry predicts prognosis in patients with heart failure with preserved ejection fraction. Int J Cardiol. 2013;168:36-40. doi: 10.1016/j.ijcard.2012.09.021
24. Elesber AA, Redfield MM, Rihal CS, Prasad A, Lavi S, Lennon R, et al. Coronary endothelial dysfunction and hyperlipidemia are independently associated with diastolic dysfunction in humans. Am Heart J. 2007;153:1081-1087. doi: 10.1016/j.ahj.2007.03.007
25. Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2012;60:1778-1786. doi: 10.1016/j. jacc.2012.07.036
26. Chan MM, Santhanakrishnan R, Chong JP, Chen Z, Tai BC, Liew OW, et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2016;18:81-88. doi: 10.1002/ejhf.431
27. Friões F, Lourenço P, Laszczynska O, Almeida PB, Guimarães JT, Januzzi JL, et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol. 2015;104:491-499. doi: 10.1007/s00392-015-0811-x
28. Izumiya Y, Hanatani S, Kimura Y, Takashio S, Yamamoto E, Kusaka H, et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol. 2014;30:338-344. doi: 10.1016/j.cjca.2013.12.010
29. Marott SC, Benn M, Johansen JS, Jensen GB, Tybj.rg-Hansen A, Nordestgaard BG. YKL-40 levels and atrial fibrillation in the general population. Int J Cardiol. 2013;167:1354-1359. doi: 10.1016/j.ijcard.2012.04.006
30. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med. 2007;357:2016-2027. doi: 10.1056/NEJMoa073600
31. Harutyunyan M, Christiansen M, Johansen JS, Køber L, Torp-Petersen C, Kastrup J. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology. 2012;217:652-656. doi: 10.1016/j.imbio.2011.11.003
32. Cleland JG, Taylor J, Tendera M. Prognosis in heart failure with a normal ejection fraction. N Engl J Med. 2007;357:829-830. doi: 10.1056/NEJMc076179
33. Hage C, Lund LH, Donal E, Daubert JC, Linde C, Mellbin L. Copeptin in patients with heart failure and preserved ejection fraction: A report from the prospective KaRen-study. Open Heart. 2015;2:e000260. doi: 10.1136/openhrt-2015-000260
34. Zabarovskaja S, Hage C, Linde C, Daubert JC, Donal E, Gabrielsen A, et al. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. Int J Cardiol. 2015;189:6-11. doi: 10.1016/j.ijcard.2015.03.381
35. Sanchez I, Santana S, Escobar C, Santiago JL, Gonzalez A, Ribas N, et al. Clinical implications of different biomarkers in elderly patients with heart failure. Biomark Med. 2014;8:535-541. doi: 10.2217/bmm.14.24
36. Szelényi Z, Fazakas A, Szénási G, Kiss M, Tegze N, Fekete BC, et al. Inflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension. J Geriatr Cardiol. 2015;12:1-10. doi: 10.11909/j.issn.1671-5411.2015.01.001
37. Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JR, et al; Alberta HEART Investigators. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One. 2014;9:e99495. doi: 10.1371/journal.pone.0099495
38. Tamaki S, Mano T, Sakata Y, Ohtani T, Takeda Y, Kamimura D, et al. Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction. PLoS One. 2013;8:e68893. doi: 10.1371/journal.pone.0068893
39. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol. 2011;57:861-869. doi: 10.1016/j.jacc.2010.10.018
40. Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 2015;17:405-415. doi: 10.1002/ejhf.244
41. Kushner I. Semantics, inflammation, cytokines and common sense. Cytokine Growth Factor Rev. 1998;9:191-196
42. Sucato V, Evola S, Novo G, Sansone A, Quagliana A, Andolina G, et al. Angiographic evaluation of coronary microvascular dysfunction in patients with heart failure and preserved ejection fraction. Microcirculation. 2015;22:528-533. doi: 10.1111/micc.12223
43. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4:312-324. doi: 10.1016/j.jchf.2015.10.007
44. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131:550-559. doi: 10.1161/CIRCULATIONAHA.114.009625
45. Ueland T, Yndestad A, Dahl CP, Gullestad L, Aukrust P. TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. Curr Heart Fail Rep. 2012;9:92-100. doi: 10.1007/s11897-012-0088-6
46. Mughal W, Dhingra R, Kirshenbaum LA. Striking a balance: Autophagy, apoptosis, and necrosis in a normal and failing heart. Curr Hypertens Rep. 2012;14:540-547. doi: 10.1007/s11906-012-0304-5
47. Niessner A, Hohensinner PJ, Rychli K, Neuhold S, Zorn G, Richter B, et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J. 2009;30:789-796. doi: 10.1093/eurheartj/ehp004
48. Halapas A, Zacharoulis A, Theocharis S, Karavidas A, Korres D, Papadopoulos K, et al. Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction. Clin Chem Lab Med. 2008;46:510-516. doi: 10.1515/CCLM.2008.091
49. Secchiero P, Corallini F, Beltrami AP, Ceconi C, Bonasia V, Di Chiara A, et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis. 2010;210:274-277. doi: 10.1016/j. atherosclerosis.2009.11.005
50. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363-14367
51. Zordoky BN, Sung MM, Ezekowitz J, Mandal R, Han B, Bjorndahl TC, et al; Alberta HEART. Metabolomic fingerprint of heart failure with preserved ejection fraction. PLoS One. 2015;10:e0124844. doi: 10.1371/journal. pone.0124844
52. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP. The resolution of inflammation. Nat Rev Immunol. 2013;13:59-66. doi: 10.1038/nri3362
53. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2:612-619. doi: 10.1038/89759
54. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-e239. doi: 10.1016/j.jacc.2013.05.019.